Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

Marie Joelle Jabagi; Jérémie Botton; Marion Bertrand; Alain Weill; Paddy Farrington; Mahmoud Zureik; Rosemary Dray-Spira

doi:10.1001/jama.2021.21699

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

JAMA. 2022 Jan 4;327(1):80-82. doi: 10.1001/jama.2021.21699.

Authors

Marie Joelle Jabagi¹, Jérémie Botton¹, Marion Bertrand¹, Alain Weill¹, Paddy Farrington², Mahmoud Zureik¹, Rosemary Dray-Spira¹

Affiliations

¹ EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France.
² School of Mathematics and Statistics, the Open University, Milton Keynes, United Kingdom.

Abstract

This population-based study evaluates the short-term risk of severe cardiovascular events among French residents aged 75 years or older after receipt of the BNT162b2 mRNA COVID-19 vaccination.

MeSH terms

Age Factors
Aged
Aged, 80 and over
BNT162 Vaccine / adverse effects*
COVID-19 / prevention & control
Databases, Factual
France / epidemiology
Humans
Incidence
Myocardial Infarction / epidemiology
Myocardial Infarction / etiology*
Pulmonary Embolism / epidemiology
Pulmonary Embolism / etiology*
Risk
Stroke / epidemiology
Stroke / etiology*

Substances

BNT162 Vaccine